Castle Biosciences CSTL Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Castle Biosciences in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The official record: Castle Biosciences’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Castle Biosciences's total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Castle Biosciences's total liabilities & equity?
- Castle Biosciences (CSTL) reported total liabilities & equity of $547.81M in Q1 2026.
- How has Castle Biosciences's total liabilities & equity changed year-over-year?
- Castle Biosciences's total liabilities & equity increased by 9.2% year-over-year, from $501.72M to $547.81M.
- What is the long-term trend for Castle Biosciences's total liabilities & equity?
- Over 5 years (2020 to 2025), Castle Biosciences's total liabilities & equity has grown at a 5.7% compound annual growth rate (CAGR), from $439.33M to $578.56M.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.